Research News for December 2010
11–20 of 27 articles
-
Researchers Recommend Having Port in Place for Week Before Starting Avastin
Research shows that doctors should wait at least 1 week after a venous access line is put in before giving Avastin.
-
Experimental Iniparib Shows Promise in Treating Advanced-Stage Disease
A small, early study suggests that some advanced-stage cancers may respond to an experimental combination of iniparib and Camptosar.
-
Prophylactic Brain Radiation Therapy Doesn’t Seem to Cause Cognitive Problems
A small, early study found that preventive cranial radiation in addition to Herceptin and chemotherapy didn't cause more or different cognitive problems than Herceptin and chemotherapy alone in women diagnosed with HER2-positive metastatic breast cancer.
-
Pathologic Complete Response to Treatment Before Surgery Linked to Better Prognosis
Research found that women who got neoadjuvant treatment and had a complete pathologic response were less likely to have the cancer come back compared to women who didn't have a complete pathologic response.
-
Xgeva Better Than Zometa at Reducing Risk of Breast Cancer Bone Problems
Research has found that Xgeva (chemical name: denosumab), a new targeted therapy medicine, is better than Zometa at lengthening the time before bone complications develop in women diagnosed with breast cancer that has spread to the bones.
-
Herceptin More Effective Than Tykerb When Given Before Surgery
Research suggests that Herceptin is more effective than Tykerb in a neoadjuvant regimen for early-stage or locally-advanced HER2-positive breast cancer.
-
Herceptin-Tykerb-Chemo Combo Before Surgery May Help Treat Early-Stage HER2-Positive Disease
Early results suggest that a combination of four medicines given BEFORE surgery to treat HER2-positive, early-stage breast cancer may be a good way to weaken and destroy breast cancer cells.
-
Arimidex and Aromasin Equally Good at Reducing Recurrence Risk
A new study shows that Arimidex and Aromasin are equally good at reducing the risk of recurrence in postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.
-
Herceptin and Tykerb Added to Chemo Before Surgery More Effective Than Adding Only One to Treat Early-Stage, HER2-Positive Disease
Giving both Herceptin and Tykerb with paclitaxel before surgery for HER2-positive breast cancer offered more benefits than Herceptin or Tykerb alone with paclitaxel new research shows.
-
Avastin Added to Chemo Before Surgery Offers No Benefit
Research shows that adding Avastin to neoadjuvant chemotherapy doesn't seem to benefit women diagnosed with early-stage or locally-advanced breast cancer.
11–20 of 27 articles
